Healthcare Industry News:  image-guided 

Devices Oncology

 News Release - February 15, 2011

BSD Medical Announces First Lung Cancer Treatment with MicroThermX(R) Microwave Ablation System at Rhode Island Hospital

SALT LAKE CITY--(Healthcare Sales & Marketing Network)-- BSD Medical Corporation (NASDAQ:BSDM ) (Company or BSD) today announced the successful delivery of its first lung cancer patient treatment with the MicroThermX® Microwave Ablation System. The treatment was conducted by Damian E. Dupuy, M.D., at The Comprehensive Cancer Center at Rhode Island Hospital (Rhode Island Hospital) in Providence, Rhode Island. Dr. Dupuy utilized the 3 antenna synchronous phased array capability of the MicroThermX® to deliver multiple ablations to a patient with a large cancerous tumor of the lung.

Referring to his first patient treatment, Dr. Dupuy stated, “The MicroThermX® is the best generator that I have used. The unique ability of the system to provide real-time feedback on the forward power delivery to the tumor is invaluable to the physician. The system provides multiple benefits to physicians and patients, including the ability to deliver ablations using multiple antennas driven by a single generator, flexibility in treatment delivery, compact size, and ease of use.”

Rhode Island Hospital is among the first in the nation to use BSD’s innovative new microwave ablation system. BSD’s initial product launch has focused on placement of a select number of systems with high-profile, interventional oncology, key opinion leaders. Rhode Island Hospital is a leading interventional oncology institution, and Dr. Dupuy, Director of Tumor Ablation at Rhode Island Hospital and a Professor of Diagnostic Imaging at The Warren Alpert Medical School of Brown University, is a key opinion leader in the field of ablation. Dr. Dupuy, a pioneer in the use of image-guided ablation, has helped broaden clinical applications of ablation to successfully combat cancer of the kidney, liver, lung, adrenal glands and skeleton. Dr. Dupuy is also a pioneer and expert in the use of the newer ablation technologies, including microwave ablation, and is currently the principal investigator of two National Cancer Institute funded multicenter trials on ablation.

About Rhode Island Hospital

Founded in 1863, Rhode Island Hospital (www.rhodeislandhospital.org) in Providence, R.I., is a private, not-for-profit hospital and is the principal teaching hospital of The Warren Alpert Medical School of Brown University. A major trauma center for southeastern New England, the hospital is dedicated to being on the cutting edge of medicine and research. Many of its physicians are recognized as leaders in their respective fields of cancer, cardiology, diabetes, emergency medicine and trauma, neuroscience, orthopedics, pediatrics, radiation oncology and surgery. Rhode Island Hospital receives nearly $50 million each year in external research funding. It is home to Hasbro Children’s Hospital, the state’s only facility dedicated to pediatric care, which is ranked among the top 30 children’s hospitals in the country by Parents magazine. Rhode Island Hospital is a founding member of the Lifespan health system.

About the MicroThermX® Microwave Ablation System

The MicroThermX® is a compact, mobile, state-of-the-art, proprietary system that includes a microwave generator, single-patient-use disposable antennas, and a thermistor-based temperature monitoring system. The innovative design is the first of its kind that allows delivery of higher power levels using a single generator. The MicroThermX® utilizes innovative synchronous phased array technology that was developed and patented by BSD to provide larger and more uniform zones of ablation during a single procedure. The MicroThermX® introduces into the Company’s product line an innovative, high-end disposable that is used in each ablation treatment, and will provide a significant ongoing revenue stream. The soft tissue ablation world market potential is estimated to exceed $2.3 billion. The U.S. Food and Drug Administration (FDA) has granted the Company a 510(k) clearance to market the MicroThermX® for ablation of soft tissue. BSD has also received CE Marking for the MicroThermX® System.

About BSD Medical Corporation

BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy delivered using focused radiofrequency (RF) and microwave energy. BSD’s product lines include both hyperthermia and ablation treatment systems. BSD’s hyperthermia cancer treatment systems, which have been in use for several years in the United States, Europe and Asia, are used to treat certain tumors with heat (hyperthermia) while increasing the effectiveness of other therapies such as radiation therapy. BSD’s microwave ablation system has been developed as a stand-alone therapy to ablate and destroy soft tissue. The Company has developed extensive intellectual property, multiple products in the market and well established distribution in the United States, Europe and Asia. Certain of the Company’s products have received regulatory approvals in the United States, Europe and China. For further information, visit BSD Medical’s website at www.BSDMedical.com.

Statements contained in this press release that are not historical facts are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to risks and uncertainties detailed in the Company’s filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date on which such statements are made, and the Company undertakes no obligation to update such statements to reflect events or circumstances arising after such date.


Source: BSD Medical

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.